image
Glaukos Corporation GKOS
Healthcare - Medical - Devices - NYSE - US
Watchlist
$ 86.07
2.89 %
$ 4.87 B
Market Cap
-31.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GKOS stock under the worst case scenario is HIDDEN Compared to the current market price of 86.1 USD, Glaukos Corporation is HIDDEN

GKOS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GKOS stock under the base case scenario is HIDDEN Compared to the current market price of 86.1 USD, Glaukos Corporation is HIDDEN

GKOS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GKOS stock under the best case scenario is HIDDEN Compared to the current market price of 86.1 USD, Glaukos Corporation is HIDDEN

GKOS Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart GKOS

image
1M -12%
6M -52%
1Y -16%
3Y 38%
5Y 154%
All
$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
383 M REVENUE
21.85%
Growth Rates
1Year 21.85%
3Years 9.26%
5Years 10.10%
7Years 13.38%
10Years 23.73%
-122 M OPERATING INCOME
4.92%
Growth Rates
1Year 4.92%
3Years -24.85%
5Years -19.46%
7Years -76.63%
10Years -24.97%
-146 M NET INCOME
-8.70%
Growth Rates
1Year -8.70%
3Years -43.44%
5Years -60.01%
7Years -186.67%
10Years -26.40%
-61.3 M OPERATING CASH FLOW
-6.16%
Growth Rates
1Year -6.16%
3Years -51.56%
5Years -178.04%
7Years -19.12%
10Years -24.05%
47.8 M INVESTING CASH FLOW
239.35%
Growth Rates
1Year 239.35%
3Years 41.30%
5Years 1.95%
7Years 29.41%
10Years 49.85%
91.5 M FINANCING CASH FLOW
508.56%
Growth Rates
1Year 508.56%
3Years 32.60%
5Years 62.96%
7Years 52.99%
10Years 38.60%
105 M REVENUE
9.13%
Growth Rates
1Year 21.85%
3Years 9.26%
5Years 10.10%
7Years 13.38%
10Years 23.73%
-28.7 M OPERATING INCOME
-16.24%
Growth Rates
1Year 4.92%
3Years -24.85%
5Years -19.46%
7Years -76.63%
10Years -24.97%
-33.6 M NET INCOME
-56.85%
Growth Rates
1Year -8.70%
3Years -43.44%
5Years -60.01%
7Years -186.67%
10Years -26.40%
507 K OPERATING CASH FLOW
105.29%
Growth Rates
1Year -6.16%
3Years -51.56%
5Years -178.04%
7Years -19.12%
10Years -24.05%
11.8 M INVESTING CASH FLOW
-61.43%
Growth Rates
1Year 239.35%
3Years 41.30%
5Years 1.95%
7Years 29.41%
10Years 49.85%
60.1 M FINANCING CASH FLOW
521.77%
Growth Rates
1Year 508.56%
3Years 32.60%
5Years 62.96%
7Years 52.99%
10Years 38.60%
Balance Sheet Glaukos Corporation
image
Current Assets 450 M
Cash & Short-Term Investments 319 M
Receivables 60.7 M
Other Current Assets 70.1 M
Non-Current Assets 525 M
Long-Term Investments 0
PP&E 170 M
Other Non-Current Assets 355 M
32.72 %6.23 %7.19 %17.43 %36.42 %Total Assets$974.8m
Current Liabilities 75.1 M
Accounts Payable 13 M
Short-Term Debt 0
Other Current Liabilities 62.1 M
Non-Current Liabilities 133 M
Long-Term Debt 103 M
Other Non-Current Liabilities 29.3 M
6.27 %29.88 %49.75 %14.10 %Total Liabilities$207.8m
EFFICIENCY
Earnings Waterfall Glaukos Corporation
image
Revenue 383 M
Cost Of Revenue 94 M
Gross Profit 289 M
Operating Expenses 412 M
Operating Income -122 M
Other Expenses 24 M
Net Income -146 M
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)383m(94m)289m(412m)(122m)(24m)(146m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.48% GROSS MARGIN
75.48%
Averages
1Year 75.48%
3Years 75.69%
5Years 72.73%
7Years 76.22%
10Years 78.81%
-31.91% OPERATING MARGIN
-31.91%
Averages
1Year -31.91%
3Years -36.32%
5Years -37.06%
7Years -30.53%
10Years -22.58%
-38.17% NET MARGIN
-38.17%
Averages
1Year -38.17%
3Years -38.68%
5Years -37.28%
7Years -26.72%
10Years -23.51%
-19.09% ROE
-19.09%
Averages
1Year -19.09%
3Years -22.32%
5Years -18.69%
7Years -14.09%
10Years -13.39%
-15.02% ROA
-15.02%
Averages
1Year -15.02%
3Years -13.08%
5Years -11.18%
7Years -8.61%
10Years -8.89%
-13.67% ROIC
-13.67%
Averages
1Year -13.67%
3Years -13.24%
5Years -11.57%
7Years -9.08%
10Years 8.12%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Glaukos Corporation
image
20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -146 M
Depreciation & Amortization 35.6 M
Capital Expenditures -6.3 M
Stock-Based Compensation 50.2 M
Change in Working Capital 0
Others -587 K
Free Cash Flow -67.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Glaukos Corporation
image
Wall Street analysts predict an average 1-year price target for GKOS of $140 , with forecasts ranging from a low of $110 to a high of $185 .
GKOS Lowest Price Target Wall Street Target
110 USD 27.80%
GKOS Average Price Target Wall Street Target
140 USD 62.38%
GKOS Highest Price Target Wall Street Target
185 USD 114.94%
Price
Max Price Target
Min Price Target
Average Price Target
2002001801801601601401401201201001008080May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Glaukos Corporation
image
Sold
0-3 MONTHS
3.16 M USD 3
3-6 MONTHS
2.61 M USD 2
6-9 MONTHS
4.83 M USD 4
9-12 MONTHS
8.88 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy. zacks.com - 1 week ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. zacks.com - 4 weeks ago
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma and corneal health solutions. zacks.com - 1 month ago
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review. benzinga.com - 1 month ago
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment. businesswire.com - 1 month ago
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern. zacks.com - 1 month ago
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - Chairman and Chief Executive Officer Joe Gilliam - President and Chief Operating Officer Conference Call Participants Tom Stephen - Stifel Richard Newitter - Truist Securities Allen Gong - JPMorgan Michael Sarcone - Jefferies Mason Carrico - Stephens Anthony Petrone - Mizuho Danielle Antalffy - UBS Operator Welcome to Glaukos Corporation's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today are available at www.glaukos.com. seekingalpha.com - 1 month ago
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago. zacks.com - 1 month ago
What to Expect From These 3 MedTech Stocks This Earnings Season? Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow. zacks.com - 1 month ago
What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. zacks.com - 1 month ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. zacks.com - 2 months ago
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20. businesswire.com - 2 months ago
8. Profile Summary

Glaukos Corporation GKOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.87 B
Dividend Yield 0.00%
Description Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Contact 229 Avenida Fabricante, San Clemente, CA, 92672 https://www.glaukos.com
IPO Date June 25, 2015
Employees 995
Officers Mr. Robert L. Davis J.D. Senior Vice President, General Counsel & Business Development Mr. L. Jay Katz FACS, M.D. Chief Medical Officer Mr. Joseph E. Gilliam President & Chief Operating Officer Mr. Chris M. Calcaterra Executive Vice President of Global Commercial Operations Mr. Christopher William Lewis Vice President of Investor Relations & Corporate Affairs Ms. Michele M. Allegretto Senior Vice President of Human Resources Mr. Alex R. Thurman Senior Vice President & Chief Financial Officer Ms. Diana A. Scherer Vice President of Compliance & Deputy General Counsel Dr. Tomas Navratil Ph.D. Chief Development Officer Mr. Thomas William Burns Chairman & Chief Executive Officer